Source comparison
BPC-157 Alternatives 2026: Mechanism Comparison
TB-500 (Thymosin Beta-4) Actin regulation, cell migration G-actin sequestration, integrin binding 2–10 mg per dose Subcutaneous Promotes cellular scaffolding before angiogenesis; peak efficacy in first 72 hours post-injury Best alternative for acute tissue rep
This comparison does not assign a generated winner or score.
- TB-500 (Thymosin Beta-4)
- Actin regulation, cell migration
- G-actin sequestration, integrin binding
- 2–10 mg per dose
- Subcutaneous
- Promotes cellular scaffolding before angiogenesis; peak efficacy in first 72 hours post-injury
- Best alternative for acute tissue repair models where cell migration is rate-limiting
- KPV Tripeptide
- NF-kB inhibition, cytokine suppression
- MC1R, MC3R melanocortin receptors
- 200 mcg–2 mg per dose
- Oral or subcutaneous
- Direct anti-inflammatory signaling vs BPC-157's indirect VEGF-mediated effects; oral bioavailability 15–25%
- Optimal for GI inflammation research due to mucosal absorption and localized effect
- Thymalin
- T-cell differentiation, immune modulation
- Thymic epithelial peptide receptors
- 5–20 mg per dose
- Intramuscular or subcutaneous
- Immune system regulation rather than tissue repair; affects adaptive immunity via thymus function
- Indicated for immune-mediated inflammation studies, not acute wound healing
- Dihexa
- Synaptogenesis, dendritic spine density
- HGF/c-Met pathway activation
- 0.1–1 mg per dose
- CNS-specific neuroregeneration vs BPC-157's peripheral neuroprotection; crosses BBB efficiently
- Only peptide alternative with direct synaptic growth promotion in hippocampal research models
- Cerebrolysin
- Neuroprotection, neurotrophic support
- Multiple neurotrophic factor mimicry
- 0.1–2.5 mL per dose
- Intramuscular
- Prevents neuronal degradation vs promoting regeneration; mimics BDNF, NGF, CNTF activity
- Suited for neurodegenerative models where cell preservation outweighs new growth